Procter & Gamble Health Limited (BOM:500126)
India
· Delayed Price · Currency is INR | Market Cap | 80.25B |
| Revenue (ttm) | 13.49B |
| Net Income (ttm) | 2.93B |
| Shares Out | 16.60M |
| EPS (ttm) | 176.59 |
| PE Ratio | 27.38 |
| Forward PE | 25.50 |
| Dividend | 125.00 (2.56%) |
| Ex-Dividend Date | Feb 12, 2026 |
| Volume | 669 |
| Average Volume | 993 |
| Open | 4,860.00 |
| Previous Close | 4,880.70 |
| Day's Range | 4,781.00 - 4,863.90 |
| 52-Week Range | 4,812.20 - 6,700.00 |
| Beta | 0.08 |
| RSI | 34.41 |
| Earnings Date | May 20, 2026 |
About Procter & Gamble Health
Procter & Gamble Health Limited manufactures and markets pharmaceuticals and chemical products in India and internationally. The company offers over-the-counter products, vitamins, minerals, and supplements. It offers its products under the Polybion, Cosome, Evion, Neurobion, Nasivion, Livogen, and Seven Seas brands. The company was formerly known as Merck Limited and changed its name to Procter & Gamble Health Limited in May 2019. Procter & Gamble Health Limited was incorporated in 1967 and is headquartered in Mumbai, India. Procter & Gamble H... [Read more]
Financial Performance
In fiscal year 2025, Procter & Gamble Health's revenue was 12.18 billion, an increase of 5.80% compared to the previous year's 11.51 billion. Earnings were 2.51 billion, an increase of 24.98%.
Financial StatementsNews
P&G Health appoints Shashank Srowthy as Executive Director and CFO, effective October 1
Procter & Gamble Health Limited (PGHL) has announced a top-level management change. The company informed exchanges on Tuesday, September 16, 2025, that Mr. Lokesh Chandak, Director & Chief Financial O...
P&G Health shares surge 8% as Q1 revenue jumps 19.5% YoY to Rs 339 crore
Shares of Procter & Gamble Health surged over 8% on Friday following the company’s robust financial performance in the first quarter of FY26. The stock touched a high of ₹6,476, rising sharply from th...
P&G Health Q2 FY25: Revenue rises 2.8% YoY to Rs 313.41 crore, net profit surges 25.6% to Rs 82.33 crore
Procter & Gamble Health Limited has reported its unaudited financial results for the quarter ended September 30, 2024, showing steady revenue growth and a notable increase in profitability. For Q2 FY2...
Procter & Gamble Health Q2 FY25 results: Stock jumps 2% ahead of result announcement
Procter & Gamble Health shares have experienced a notable increase, jumping more than 2% ahead of Q2 FY25 results. The stock opened at Rs 5,367.70, reaching a high of Rs 5,380.00 during trading hours,...